Fractyl Health, a biotech company based in Burlington, Massachusetts, plans to cut about 45% of its workforce, according to a filing with the Securities and Exchange Commission. The company said Oct. 22 that it will concentrate its money and staff on Revita, an endoscopic procedure it is developing to help people keep weight off after they stop taking GLP-1 drugs.
The company adopted the plan Oct. 21, according to the filing. Fractyl said the move follows six-month results from its REMAIN-1 pivotal study, which the company said met a prespecified co-primary endpoint for weight regain compared with a sham procedure. Fractyl also said it will discontinue internal development of its Rejuva gene therapy program and is seeking strategic alternatives for it.
Fractyl estimated about $2 million in charges for severance and other employee termination-related costs, most of it in the fourth quarter of 2026, according to the filing. The filing says the reduction is expected to be completed during the fourth quarter. The company's news release says it is expected to be substantially completed by November 2026. Fractyl said it expects its cash to fund operations into the second quarter of 2027.
"While these decisions are difficult, particularly those impacting our colleagues, we believe this focused strategy will position Fractyl to operate more efficiently and advance Revita toward its clinical and commercial potential," Harith Rajagopalan, Fractyl's co-founder and chief executive, said in the release.
The company said Oct. 22 that Jay Caplan, a co-founder who was president and chief product officer, would retire from those roles Oct. 30 and stay on as a senior advisor. It said Rajagopalan would become president on that date, in addition to remaining chief executive.
The 45% figure applies to the whole company. The Oct. 22 filing and release do not say how many employees will lose their jobs or which roles or locations are affected. Fractyl said it plans to submit a De Novo marketing application to the Food and Drug Administration for Revita late in the fourth quarter of 2026.
Sources: Fractyl Health Form 8-K, Oct. 22, 2026; Fractyl Health news release, Oct. 22, 2026.

